Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pradofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 5/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 5/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pradofloxacin SCHEMBL7488977 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL150884 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7678035 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL30595280 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7962325 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7962442 | 0.96 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7976296 | 0.95 | KDM4E (0.69) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL9181426 | 0.92 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7962516 | 0.90 | KDM4E (0.67) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7975579 | 0.90 | KDM4E (0.63) | ALDH1A1KDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977484-B2 | Pradofloxacin trihydrate; thermodynamically stable and is not converted to other crystal forms even during prolonged storage; non-hygroscopic | BAYER ANIMAL HEALTH GMBH (DE) | 2011-07-12 | — | — | US | claimed |
| CN-100591681-C | Novel crystalline forms of 8-cyano-1-cyclopropyl-7- (1S, 6S-2, 8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid | BAYER HEALTHCARE AG | 2010-02-24 | — | — | CN | claimed |
| EP-1737859-B1 | NOVEL CRYSTALLINE FORM OF 8-CYANO-1-CYCLOPROPYL-7-(1S,6S-2,8-DIAZABICYCLO¬4.3.0 NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINE CARBOXYLIC ACID | BAYER ANIMAL HEALTH GMBH (DE) | 2009-12-02 | — | — | EP | claimed |
| US-20080125458-A1 | Novel Crystalline Form Of Cyano-1-Cyclopropyl-7-1S,6S-2,8-Diazabicyclo[4.3.0]Nonan-8-Yl) -6-Fluoro-1,4-Dihydro-4-Oxo-3-Quinoline Carboxylic Acid | BAYER HEALTHCARE AG (DE) | 2008-05-29 | — | — | US | claimed |
| CN-1938304-A | Novel crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid | BAYER HEALTHCARE AG (DE) | 2007-03-28 | — | — | CN | claimed |
| US-11617792-B2 | Liquid composition containing pradofloxacin | BAYER ANIMAL HEALTH GMBH (DE) | 2023-04-04 | — | — | US | disclosed |
| EP-3579820-B1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | BAYER ANIMAL HEALTH GMBH (DE) | 2021-04-28 | — | — | EP | disclosed |
| US-20200376126-A1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | BAYER ANIMAL HEALTH GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10780168-B2 | Liquid composition containing pradofloxacin | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-20200030449-A1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | ELANCO ANIMAL HEALTH GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-110248643-A | Liquid composition containing Pradofloxacin | 拜耳动物保健有限责任公司 | 2019-09-17 | — | — | CN | disclosed |
| WO-2018146194-A1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | BAYER ANIMAL HEALTH GMBH (DE) | 2018-08-16 | — | — | WO | disclosed |
| US-20100261688-A1 | STABILIZATION OF OILY SUSPENSIONS COMPRISING HYDROPHOBIC SILICAS | BAYER ANIMAL HEALTH GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| CN-101861169-A | Stabilisation of oily suspensions containing hydrophobic silicic acids | BAYER ANIMAL HEALTH GMBH | 2010-10-13 | — | — | CN | disclosed |
| CN-100591681-C | Novel crystalline forms of 8-cyano-1-cyclopropyl-7- (1S, 6S-2, 8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid | BAYER HEALTHCARE AG | 2010-02-24 | — | — | CN | disclosed |
| US-20090239835-A1 | STABILIZATION OF GLUCOCORTICOID ESTERS WITH ACIDS | BAYER HEALTHCARE AG (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090011045-A1 | Pharmaceutical for Hygienic Administration in the Ear | BAYER HEALTHCARE AG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20080125458-A1 | Novel Crystalline Form Of Cyano-1-Cyclopropyl-7-1S,6S-2,8-Diazabicyclo[4.3.0]Nonan-8-Yl) -6-Fluoro-1,4-Dihydro-4-Oxo-3-Quinoline Carboxylic Acid | BAYER HEALTHCARE AG (DE) | 2008-05-29 | — | — | US | disclosed |
| CN-101090707-A | Medicament for hygienic administration in the ear | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| CN-1938304-A | Novel crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid | BAYER HEALTHCARE AG (DE) | 2007-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125458-A1 | Novel Crystalline Form Of Cyano-1-Cyclopropyl-7-1S,6S-2,8-Diazabicyclo[4.3.0]Nonan-8-Yl) -6-Fluoro-1,4-Dihydro-4-Oxo-3-Quinoline Carboxylic Acid | TOP1, NDUFA6, TALDO1 | ALDH1A1 1311/4885KDM4E 2280/4885HPGD 1217/4885 |
| US-20200376126-A1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | MTHFD2, MTHFD1, GCDH | ALDH1A1 2234/4885KDM4E 4157/4885HPGD 75/4885 |
| US-10780168-B2 | Liquid composition containing pradofloxacin | MTHFD2, MTHFD1, GCDH | ALDH1A1 2234/4885KDM4E 4157/4885HPGD 75/4885 |
| US-20090011045-A1 | Pharmaceutical for Hygienic Administration in the Ear | HINT1, OTC, HES1 | ALDH1A1 548/4885KDM4E 2529/4885HPGD 551/4885 |
| US-20200030449-A1 | LIQUID COMPOSITION CONTAINING PRADOFLOXACIN | MTHFD2, MTHFD1, GCDH | ALDH1A1 2234/4885KDM4E 4157/4885HPGD 75/4885 |
| US-11617792-B2 | Liquid composition containing pradofloxacin | MTHFD2, MTHFD1, GCDH | ALDH1A1 2234/4885KDM4E 4157/4885HPGD 75/4885 |
| US-20100261688-A1 | STABILIZATION OF OILY SUSPENSIONS COMPRISING HYDROPHOBIC SILICAS | LIPA, SGMS2, MSN | ALDH1A1 4626/4885KDM4E 4053/4885HPGD 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.